# Prospective ARNI vs ACE Inhibitor Trial to DetermIne Superiority in Reducing Heart Failure Events After MI

Study · id `cardio:ct-nct02924727` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02924727](<https://clinicaltrials.gov/study/NCT02924727>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02924727

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Acute care and long-term living  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 5669 participants.

## Technical summary

Registry record NCT02924727. Randomized; quadruple masking; primary purpose treatment. Start 2016-12-09 (actual); primary completion 2021-02-26 (actual). Results posted on 2023-06-22.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 5669 participants (enrolled count; ClinicalTrials.gov record NCT02924727, source copy `cardio:ctgov-nct02924727-2023-06-22`, retrieved 2026-10-26)
- Started: 2016-12-09 (actual) (ClinicalTrials.gov record NCT02924727, source copy `cardio:ctgov-nct02924727-2023-06-22`, retrieved 2026-10-26)
- Primary completion: 2021-02-26 (actual) (ClinicalTrials.gov record NCT02924727, source copy `cardio:ctgov-nct02924727-2023-06-22`, retrieved 2026-10-26)
- Completion: 2021-02-26 (actual) (ClinicalTrials.gov record NCT02924727, source copy `cardio:ctgov-nct02924727-2023-06-22`, retrieved 2026-10-26)
- Results first posted: 2023-06-22 (ClinicalTrials.gov record NCT02924727, source copy `cardio:ctgov-nct02924727-2023-06-22`, retrieved 2026-10-26)
- Countries: United States; Argentina; Australia; Austria; Belgium; Brazil; Bulgaria; Canada; China; Colombia; Croatia; Czechia; Denmark; Finland; France; Germany; Greece; Hungary; India; Israel; Italy; Mexico; Netherlands; Norway; Peru; Philippines; Poland; Portugal; Romania; Russia; Singapore; Slovakia; South Africa; South Korea; Spain; Sweden; Switzerland; Taiwan; Thailand; Türkiye; United Kingdom (ClinicalTrials.gov record NCT02924727, source copy `cardio:ctgov-nct02924727-2023-06-22`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02924727-2023-06-22`, retrieved 2026-10-26)

## The registry's words

- Brief title: Prospective ARNI vs ACE Inhibitor Trial to DetermIne Superiority in Reducing Heart Failure Events After MI
- Acronym: PARADISE-MI
- Condition: Acute Myocardial Infarction
- Intervention (Drug): LCZ696 (sacubitril/valsartan)
- Intervention (Drug): Ramipril
- Intervention (Drug): Placebo of LCZ696
- Intervention (Drug): Placebo of ramipril
- Intervention (Drug): Valsartan
- Intervention (Drug): Placebo of valsartan
- Lead sponsor: Novartis Pharmaceuticals
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry condition terms include this condition: Non-ST-elevation heart attack (NSTEMI) (`cardio:nstemi`)
- Registry condition terms include this condition: ST-elevation heart attack (STEMI) (`cardio:stemi`)
- Registry intervention name matches this record: Ramipril (`cardio:ramipril`)
- Registry intervention name matches this record: Valsartan (`cardio:valsartan`)
- Registry lists this organization as the lead sponsor: Novartis (`cardio:novartis`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Angiotensin Receptor-Neprilysin Inhibition in Acute Myocardial Infarction (`cardio:pubmed-34758252`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Impact of Sacubitril/Valsartan Compared With Ramipril on Cardiac Structure and Function After Acute Myocardial Infarction: The PARADISE-MI Echocardiographic Substudy (`cardio:pubmed-36082663`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: The Effects of Angiotensin Receptor-Neprilysin Inhibition on Major Coronary Events in Patients With Acute Myocardial Infarction: Insights From the PARADISE-MI Trial (`cardio:pubmed-36321459`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Prognostic Importance of NT-proBNP (N-Terminal Pro-B-Type Natriuretic Peptide) Following High-Risk Myocardial Infarction in the PARADISE-MI Trial (`cardio:pubmed-37125529`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Sex Differences in Clinical Characteristics and Outcomes After Myocardial Infarction With Low Ejection Fraction: Insights From PARADISE-MI (`cardio:pubmed-37609931`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Angiotensin Receptor-Neprilysin Inhibition in Patients With STEMI vs NSTEMI (`cardio:pubmed-38418004`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Rates of Sudden Death After Myocardial Infarction-Insights From the VALIANT and PARADISE-MI Trials (`cardio:pubmed-39110471`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 63b31eddc4448069065454e77a641115add412ccf7e2d8458bc7f7ab5586c824
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
